![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, January 16, 2009 2:57:42 PM
DNAPrint Genomics is no "sham company." It is, as we very well know, a company that is struggling with financing issues. That does not, in any way, shape, or form, make it a "sham company."
As for the lab instrument that Sarah told me was currently down, she said it should be back up and running within "a few weeks."
What do you expect from microcap research and development stocks, struggling with financing issues? I think DNAG has been extremely reserved in the issuance of new shares, relative to other companies in similar situations. People who buy such stocks only have themselves to blame, if they don't understand the realities surrounding such stocks. Get-rich-quick-with-no-risk dreams are delusional.
In my opinion, DNAPrint Genomics well deserves to succeed. It is gratifying to see that the constant reports of its demise, have been greatly exaggerated. (For some reason, I never see any retractions from the "detractor" aliases, no matter how often they are proven wrong.)
Daniel
FEATURED POET and Luxshare Tech Expand Product Offerings for Artificial Intelligence Networks • Aug 1, 2024 9:28 AM
Management Discusses Financial Filings of Global Arena Holding Inc., for 10-K 2023 and 10-Q, 1st Quarter 2024 • GAHC • Aug 1, 2024 9:14 AM
VAYK Announces LOI to Acquire $1 Million Home Service Company to Support Airbnb Business • VAYK • Aug 1, 2024 9:00 AM
Duane Forrester Joins INDEXR as SVP of Search • MONI • Jul 31, 2024 11:46 AM
Lingerie Fighting Championships Help Fulfill Death-Bed Promise With First Major Motion Picture • BOTY • Jul 31, 2024 9:00 AM
Kona Gold Beverage Significantly Reduces Debt from Multiple Holders • KGKG • Jul 31, 2024 9:00 AM